C-erbB-2/HER-2 (designated HER-2) is overexpressed in both primary and metastatic breast cancer and predicts poor prognosis. We investigated the expression of HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy (HDCT) with autologous blood stem cell (ABSC) support and correlated the presence (positive) or absence (negative) of HER-2 overexpression in these patients with response to treatment, progression-free survival (PFS) and overall survival (OS). The level of HER-2 expression was analyzed in 57 patients with metastatic breast cancer undergoing HDCT with ABSC support. Plasma from peripheral blood was taken at three different time points during the course of treatment and was analyzed using an enzyme immunoassay (EIA) to detect circulating levels of the extracellular portion of HER-2. HER-2 levels were elevated (Ͼ0.2 U/mg protein) in 27/57 (47.4%) patients at one or more time points during treatment. The level of HER-2 varied during the course of treatment. Following induction chemotherapy (ICT), five patients who were negative initially, showed overexpression of HER-2. Three patients overexpressed HER-2 only after HDCT/ABSC. Response to treatment was similar in patients independent of plasma HER-2 levels. Overexpression of HER-2 was associated with a significantly shorter PFS (P = 0.004, log rank) and OS (P = 0.003, log rank) after HDCT/ABSC. HER-2 overexpression, patient age, estrogen receptor status, progesterone receptor status, and previous hormone treatment were assessed by univariate and multivariate analysis. Univariate analysis determined that only HER-2 overexpression correlated significantly with decreases in progression free survival (P = 0.005, Cox regression). Decreased overall survival correlated significantly with HER-2 overexpression (P = 0.004) and decreased expression of both estrogen receptor (P = 0.032) and progesterone receptor (P = 0.039). In multivariate analysis of these variables, only HER-2 expression levels proved to be of independent statistical significance in predicting outcome for both PFS (P = 0.007) and OS Correspondence: Dr S Glück, Depts Oncology, Medicine, and Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Tom Baker Cancer Centre, 1331, 29th Street NW, Calgary, Alberta, Canada Received 18 August 1998; accepted 5 May 1999 (P = 0.002). These results suggest that overexpression of HER-2, measured by EIA in plasma may predict a shorter PFS and OS in patients with metastatic breast cancer treated with HDCT and ABSC support.
The proto-oncogene c-erbB-2/neu HER-2 resides on chromosome 17 and encodes a 185 kDa transmembrane glycoprotein (designated HER-2) with intracellular tyrosine kinase activity.
1 HER-2 is a member of the EGF growth factor receptor family which consists of four closely related family members: the EGF receptor (EGFR, ERBB1), HER-2 (ERBB2/NEU), HER-3 (ERBB3) and HER-4 (ERBB4). 2 Both homodimers and heterodimers are formed among the various family members mediating a complex system of signal transduction affecting both cell proliferation and growth. [2] [3] [4] [5] [6] The importance of these growth factor receptors on the growth and regulation of breast cancer has been demonstrated. Overexpression and/or amplification of HER-2 was found in more than 20-30% of primary breast tumours and to varying degrees in other cancers (ovarian, gastric, colorectal, lung, salivary, bladder, pancreas, endometrial, cervical, oral and prostate). [7] [8] [9] [10] [11] [12] Both HER-2 overexpression and gene amplification were often found to correlate with poorer survival, particularly in patients with involvement of lymph nodes with breast cancer. [7] [8] [9] [10] [11] [12] [13] [14] Although HER-2 oncoprotein overexpression correlates with reduced patient survival, few studies have evaluated the incidence of HER-2 overexpression in patients with metastatic breast cancer (MBC) and examined whether increased levels of this protein indicate a poorer prognosis and/or reduced responsiveness to systemic treatment. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] In these studies, 30-50% of patients with MBC had elevated levels of circulating (plasma, serum) extracellular domain of HER-2. [14] [15] [16] [17] [18] [19] Overexpression correlates with an increased tumour burden and reduced survival. [14] [15] [16] 18, [22] [23] [24] [25] Since EIA (enzyme immunoassay) is a relatively simple assay commonly used in clinical medicine, the possibility that elevated levels of extracellular HER-2 could indicate poor prognosis in patients with MBC is of particular interest.
High-dose chemotherapy (HDCT) followed by autolog-ous blood stem cell (ABSC) support is rapidly becoming the preferred treatment for patients with MBC, high risk stage II and stage III breast cancer in the United States. 26 Little is known about the incidence of HER-2 gene overexpression in patients with MBC undergoing this treatment and whether increased levels of this protein indicate a poor prognosis and/or a reduced responsiveness to this treatment.
In this retrospective study, we examined the incidence of overexpression and changes in the levels of HER-2 protein in the plasma of 57 patients with advanced breast cancer treated with HDCT and ABSC support. Results were analyzed and correlated with response to treatment, progression-free survival (PFS) and overall survival (OS).
Materials and methods

Patients
Peripheral blood and ABSC specimens were collected during the course of treatment of 57 patients with metastatic breast cancer (MBC) enrolled into clinical trials using HDCT and ABSC transplantation. Patients were between 19 and 55 years of age, had hormone receptor-negative tumours or had failed at least one hormone treatment regimen for MBC. The median age was 43 years. The WHO performance status was 0, 1 or 2. The majority of patients had a performance status of 0 and 1. Initial breast cancer presentation, was as follows: six patients in stage I, 30 patients in stage II and seven patients in stage III. The remaining 14 patients initially presented with metastatic disease (stage IV). The number of metastatic sites was one or two for the majority of patients at enrolment into the clinical trials using HDCT and ABSC transplantation. Seventeen of these patients had only bony metastasis, seven patients had only metastasis in the lymph nodes, and nine patients had visceral metastasis in the liver and/or lung. Five patients had three or more metastatic sites. Patients with CNS metastasis were excluded from this study. The majority of patients had previously received adjuvant chemotherapy consisting of either cyclophosphamide (CTX), methotrexate, 5-fluorouracil (CMF) or an anthracycline-containing regimen. Twenty-four patients had previously received hormone treatment.
These studies were approved by the Research Ethics Board (REB), Laurentian Hospital, Sudbury, Ontario, Canada and the patients were enrolled into a clinical trial only when they fulfilled the entry criteria and signed an informed consent.
All patients received treatment initially consisting of two cycles of induction chemotherapy (ICT). This consisted of CTX, 500 mg/m 2 body surface area (BSA) intravenously (i.v.), doxorubicin (DOX), 50 mg/m 2 BSA i.v. or epirubicin (EPI), 60 mg/m 2 BSA i.v. and 5-FU, 500 mg/m 2 BSA i.v. Patients whose tumours did not progress after these two cycles continued on the study which included further ICT using dose-escalation of CTX to 2000 mg/m 2 BSA i.v. with the same doses of DOX or EPI and 5-FU. CD34
+ cells were mobilized with either rhGM-CSF or rhG-CSF at 5 or 10 g/kg, body weight (BW) starting 1 day after ICT. An apheresis procedure (AP) was performed for an average of 4 consecutive days after the rebound phase was reached (when WBC values increased to Ͼ2.5 × 10 9 /l) using a blood cell separator (Fenwal CS 3000 Plus (Baxter Healthcare, Deerfield, IL, USA) or COBE (COBE Laboratories, Lakewood, CO, USA)). A total blood volume of 10 litres per AP was processed at a flow rate of 60-70 ml/min. AP collections were continued until a minimum of 2 × 10 6
CD34
+ cells/kg BW were obtained as determined by standard flow cytometric evaluation.
The majority of patients (n = 44) received HDCT consisting of total doses of CTX (6 g 27 
HER-2 plasma levels
HER-2 plasma levels were determined using the HER-2 serum EIA kit (Chiron Diagnostics, formerly Triton Diagnostics, Alameda, CA, USA) according to the manufacturer's instructions. This kit uses a monoclonal antibodybased immunoenzymatic assay to quantify the shed HER-2 fragment in plasma.
Plasma samples were collected at several time points during the course of patient treatment and stored at −80°C until analysis and evaluation for HER-2 levels. In brief, blood samples were collected in ethylene-diaminetetraacetic acid (EDTA) vacutainer tubes. Plasma was collected by centrifugation at 400 g for 10 min. The plasma was removed, frozen in aliquots and stored at −80°C until required for assay. Plasma HER-2 levels were examined at three different time points: (1) at initial enrolment to the clinical program; (2) at the time of first or second apheresis (after ICT with rhGM-CSF or rhG-CSF); (3) approximately 1 month after HDCT and ABSC reinfusion. Before assay, frozen plasma samples were thawed gradually and centrifuged at 8000 g for 5 min in Eppendorf tubes. Protein con-centration was measured by the Bradford protein dye method, 28 using bovine serum albumin as the standard. Measurements of HER-2 levels in plasma of seven healthy women resulted in a mean concentration of 13.8 U/ml Ϯ 2.3 s.d. To further offset any variation due to patient plasma differences during treatment, data were expressed as U/mg plasma protein or 0.134 U/mg protein Ϯ 0.02 s.d. The cut-point for positivity (ie overexpression) was defined as 21 U/ml or 0.2 U/mg protein (using the mean plus three times the standard deviation calculation from Isola et al 24 ) . Plasma samples expressing HER-2 levels below this cut-point were defined as 'HER-2 negative' and those samples equal to or above this cut-point were defined as 'HER-2 positive.' More significant differences between the HER-2 positive and negative patient populations were found when the data were calculated and analyzed using the 0.2 U/mg protein cut-point and all data were subsequently evaluated using this cut-point.
Patient evaluation and statistical analysis
Progression-free survival (PFS) was defined as the time from study entry to documented signs of recurrence or progression of disease. Overall survival (OS) was defined as the time from study entry to death due to MBC. Survival curves were calculated using the Kaplan-Meier method. Differences between survival times were analyzed by the log-rank, Wilcoxon and Cox tests for survivorship functions and hazard ratios were calculated by Cox's proportional hazards method for univariate analysis.
Patient treatment response was determined by physical and radiological evaluation according to the World Health Organization (WHO) criteria 29 at various established times during the course of treatment and subsequently every 2-3 months for 2 years and then every 6 months until evidence of relapse.
Patients were considered to have achieved a complete response (CR) if there was disappearance of all known disease at re-evaluation. Partial response (PR) was defined as a 50% or more reduction in total tumour load of the lesions that have been measured, no appearance of new lesions or progression of any lesion. Stable disease (SD) was defined as no significant change (not more than 25% above or 50% below prestudy size) in evaluable disease. Progressive disease (PD) was defined as a 25% or more increase in the minimum size of one or more measurable lesions or the presence of new metastatic lesions.
Only patients with CR or PR were considered to have responded to treatment. Fisher's exact test was used to test for response difference according to HER-2 expression levels. Table 1 shows the number of samples overexpressing HER-2 at each serial measurement. Plasma HER-2 levels were examined at three time points: (1) at initial enrolment to the clinical trial; (2) after ICT, at the time of apheresis; (3) at the 4-6 week restaging after HDCT and ABSC support.
Results
HER-2 levels during treatment
It should be noted that not all three plasma samples were available for measurement in some patients. Overall, it was found that 27 of the 57 patients examined over-expressed HER-2 (Table 1) at one or more of the time-points examined. The HER-2 EIA results of these HER-2 positive patients were then examined at each of the time-points. At the first time-point, plasma samples from 25 of the 27 patients that were found to be HER-2 positive at any time in this study were available for analysis. Sixteen of these 25 patients (64%) were HER-2 positive at this time-point. At the second time-point, samples from all 27 HER-2 positive patients were available for analysis. Twenty-one of these 27 patients (77.8%) over-expressed HER-2 at this time-point including five patients who were negative at the initial measurement. At the third time-point (after HDCT and ABSCT), plasma samples from 24 of the 27 HER-2 positive patients were available for assessment. Thirteen of these 24 patients (54.2%) overexpressed HER-2 including three patients who were negative at the two previous measurements. Plasma samples from all three time-points were available from 24 of the 27 HER-2 positive patients. Only eight of these 24 patients (33.3%) over-expressed HER-2 at all three time-points.
The mean levels of secreted HER-2 decreased during the course of treatment in 17 of 22 evaluated patients who were HER-2 positive initially and/or at time of apheresis. In eleven of these 17, the values decreased below the cut-point of 0.2 U/mg protein after HDCT and ABSC re-infusion.
Survival and clinical course analysis
Patients who overexpressed levels of HER-2 (Ͼ0.2 U/mg) on at least one occasion were considered HER-2 positive. Twenty-four HER-2 negative patients responded to chemotherapy (17 PR and 7 CR) and 21 HER-2 positive patients responded to treatment (17 PR and 4 CR). The total number of nonresponders (PD + SD) was five for both HER-2 positive and HER-2 negative patients. (Two patients were not assessed.) There was no significant difference in the response to chemotherapy between HER-2 positive and HER-2 negative patients (Fisher's exact test, data not shown).
HER-2 overexpression, patient age, estrogen receptor status, progesterone receptor status, and previous hormone treatment were assessed by univariate and multivariate analysis. Univariate analysis determined that only HER-2 overexpression correlated significantly with decreases in progression-free survival (P = 0.005, Cox regression). Decreased overall survival correlated significantly with HER-2 overexpression (P = 0.004) and decreased expression of both estrogen receptor (P = 0.032) and progesterone receptor (P = 0.039). In multivariate analysis, only HER-2 expression levels proved to be of independent statistical significance in predicting outcome for both PFS (P = 0.007) and OS (P = 0.002).
OS and PFS analysis using the Kaplan-Meier method for HER-2 expression levels are shown in Table 2 . The median OS for all patients on this study was 25.1 months; and the median PFS was 10.4 months. Figure 1a and b show the OS and PFS curves respectively, of patients with plasma positive and negative HER-2 expression. The difference in OS was highly significant between patients with HER-2 negative and HER-2 positive plasma using the log-rank test (P = 0.003), Wilcoxon (P = 0.0018) and Cox tests (P = 0.0040). The overall median survival for HER-2 positive patients was 17.2 months and for HER-2 negative patients, was 28.9 months. The relative risk or hazard ratio was 2.5.
Differences in the duration of PFS were also highly significant using the log-rank test (0.004), Wilcoxon (0.007) and Cox tests (0.005) (see Table 2 ) between HER-2 plasma positive and negative patients. The median PFS of HER-2 plasma positive patients was 7.5 months compared with 14.3 months for HER-2 negative patients. The relative risk or hazard ratio was 2.3.
There were no significant differences in OS and PFS between the group of patients who initially overexpressed HER-2 (at the first measurement) and that continued to overexpress HER-2 (six patients) after HDCT/ABSC support and those patients that initially overexpressed HER-2 and then became HER-2 negative after HDCT/ABSC support (11 patients) (data not shown).
An independent analysis at each of the three serial measurements for HER-2 expression was performed. Analysis of the PFS showed that only the hazard ratio at the second measurement (at the time of apheresis) was significant for those patients which overexpressed HER-2 and those that did not (hazard ratio: 2.04, 95%CI 1.14-3.65, P = 0.017).
Analysis of OS at each time-point showed significant differences in hazard ratio between the HER-2 positive and HER-2 negative group at the second measurement (hazard ratio: 2.66, 95% CI: 1.40-5.05, P = 0.003) and also at the initial measurement (hazard ratio: 2.25, 95% CI: 1.15-4.43, P = 0.018).
Since several HDCT regimens were used in this study, the effect of treatment regimen on survival outcome in HER-2 positive and HER-2 negative patients was also examined. The HDCT regimens for the HER-2 positive patient group were as follows: eight patients received carboplatin, mitoxantrone and CTX; 13 patients received vinblastine, mitoxantrone and CTX; three patients did not go on to HDCT; three patients received two HDCT treatments: patient 1 received carboplatin, mitoxantrone and CTX followed by vinblastine, mitoxantrone and CTX, patient 2 received carboplatin, mitoxantrone and CTX followed by thiotepa and CTX and patient 3 received vinblastine, mitoxantrone and CTX followed by carboplatin, mitoxantrone and CTX. The HDCT regimens for HER-2 negative patients consisted of the following: 14 patients received carboplatin, mitoxantrone and CTX; nine patients received vinblastine, mitoxantrone and CTX; three patients did not go on to HDCT; two patients received taxol, mitoxantrone and CTX; two patients received two HDCT treatments consisting of vinblastine, mitoxantrone and CTX followed by carboplatin, mitoxantrone and cyclophosphamide.
Comparison of survival curves of various treatment groups using the log rank test showed no significant differences in overall or relapse-free survival between HER-2 positive patients that received either vinblastine or carboplatin in their treatment regimen. Within the group of HER-2 negative patients, no significant differences in overall or relapse-free survival were found between those patients receiving either carboplatin or vinblastine in the HDCT treatment regimen. However, significant differences in overall and progression-free survival were found between HER-2 positive and negative patients receiving carboplatin and for progression-free survival of patients receiving vinblastine. Overall survival results were not quite significant between HER-2 positive and HER-2 negative patients treated with vinblastine (data not shown). Five patients received two HDCT regimens: three were HER-2 positive and two were HER-2 negative. In each of the groups, there was one patient surviving at the time of analysis. Significant differences in survival (OS and PFS) between HER-2 positive and HER-2 negative patients were obtained after removal of these five patients from the analysis (for OS: P = 0.002, median overall survival of HER-2 positive group: 12.73 months, median survival of HER-2 negative group: 28.9 months, hazard ratio: 2.7; and for PFS the results were determined to be extremely significant: P = 0.0002, median survival of HER-2 positive group was 6.94 months, median survival for HER-2 negative was 16.57 months, hazard ratio: 3.0).
Discussion
A simple, quantitative EIA procedure was used to examine HER-2 overexpression in plasma samples from 57 metastatic breast cancer patients. These patients were enrolled in clinical trials of HDCT with ABSC support. Entry criteria included patients who had failed hormone therapy or whose disease was hormone receptor negative.
No clear cutoff value for HER-2 overexpression has been established in a variety of studies using this procedure and previous studies have individually determined the cut-point for HER-2 overexpression in patient serum and plasma in various ways. Isola et al 24 examined HER-2 levels in preoperative and follow-up serum samples in patients with breast cancer using the EIA assay manufactured by Triton (now Chiron) Diagnostics. Serum levels in 113 patients with benign breast disease had a mean of 5.7 Ϯ 4.8 s.d. U/ml and the cut-point for positivity was defined as 20 U/ml (using the mean plus three times the standard deviation calculation). Revillion et al 17 using the HER-2 plasma assay manufactured by Triton (Chiron) determined a cutoff value of 27 U/ml in healthy women (n = 30). Volas et al 20 selected a cut-point of 30 U/ml also based on serum results of healthy controls also using the same EIA kit. Kandl et al 14 measured the HER-2 antigen fragment in the serum of 79 women with advanced breast cancer. They found that a serum concentration of Ͼ10 U/ml had a significant impact on OS from the time of diagnosis of metastatic disease.
We determined the cut-point for HER-2 overexpression using plasma from normal blood samples to be 21 U/ml. This value was similar to that of other investigators using this method and assay kit and resulted in significant survival differences between HER-2 expression groups. Optimal cut-points have also been previously defined by determining a value which results in the most significant difference between the two groups. 24 After normalizing for plasma protein, a cut-point of 0.2 U/mg plasma protein was obtained, offsetting any sample variations in the amount of plasma protein. Protein in plasma samples was found to vary considerably, particularly during ICT (range 45.6 mg/ml to 125.7 mg/ml) using the Bradford protein determination method 28 and may be due to the effects of treatment. ICT using growth factors increases the number of circulating cells including hematopoietic cells and may directly or indirectly influence plasma protein. Disease status and general health of each patient and even the quality of the stored plasma may influence plasma protein content. Normalizing HER-2 expression for total protein resulted in better discrimination between the HER-2 positive and negative groups.
Serial changes in HER-2 overexpression were measured in this study. These results show that changes in HER-2 levels can occur during therapy and that patients can have both negative and positive HER-2 levels during the course of treatment. In three of the 27 HER-2 overexpressing patients, HER-2 was detected only after HDCT and ABSC transplantation. Five patients who were negative at the initial measurement were found to overexpress HER-2 at the second measurement after ICT at apheresis. Revillion et al, 17 using the same EIA method, also observed that five of 23 initially HER-2 negative advanced breast cancer patients became HER-2 positive (overexpressing) during treatment with chemotherapy. Serial changes in HER-2 plasma levels were also observed by Isola et al. 24 Serial changes could be attributed to the quality of the stored plasma sample and changes in the tumour burden and/or HER-2 fragment released from these tumours during the course of treatment. In patients who overexpressed HER-2 before HDCT, there were no significant differences in OS and PFS between those who lost HER-2 overexpression (11/17) or maintained overexpression (6/17) after HDCT (data not shown). This suggests that the sensitivity of the detection method with decreasing tumour burden is limiting. HER-2 overexpression by tumours, independent of the release of the HER-2 soluble fragment in the plasma, may predict survival outcome. These results are similar to outcomes of studies showing that changes in HER-2 overexpression do not correlate with clinical outcome. [17] [18] [19] [20] Chemotherapy and cytokine treatments used to mobilise haematopoietic stem cells into blood can also mobilise tumour cells and the observed increase in the number of patients with circulating HER-2 after ICT may be related to this effect. 30, 31 ICT may also increase the amount of soluble HER-2 fragment released from tumours containing HER-2 overexpressing cells. In this study, if only an initial measurement of HER-2 had been determined, eight patients who were actually positive for HER-2 overexpression would have been excluded. Therefore, during treatment more than one measurement (or a determination of the optimal timing of measurement) with this method may be necessary in order to evaluate HER-2 expression. An analysis of PFS and OS at each time-point in relation to HER-2 overexpression showed that for both PFS and OS, the hazard ratio at the second measurement (at apheresis, following ICT with rhG-CSF or rhGM-CSF growth factor) showed significant survival differences suggesting this may be the optimum time to evaluate HER-2 overexpression before HDCT.
In this study, 47.4% of patients with MBC overexpressed HER-2. This is consistent with that found in the few studies that have examined overexpression in MBC; ie 20-57% of patients with MBC have elevated HER-2 plasma concentrations. [14] [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] The HER-2 positive patients in this study had a significantly decreased OS and PFS following HDCT and ABSC transplantation ( Table 2 and Figures 1 and 2) . Therefore, the presence of elevated plasma HER-2 may be an important prognostic factor that could be used to select more effective and additional therapies for these patients (eg directly targeted treatments using immunologic therapy).
It is still not certain whether patients with elevated levels of HER-2 would benefit more from specific and/or increased dosages of chemotherapeutic agents as suggested previously in some clinical studies. [32] [33] [34] [35] Results from a study by Muss et al 32 suggest that patients with node positive early breast cancer who overexpress HER-2 may benefit from higher doses of adjuvant chemotherapy particularly when using doxorubicin. Results of this retrospective study indicate that increased dosages of the drugs used in HDCT do not significantly improve response and survival in patients with MBC who overexpress HER-2.
HER-2 overexpression has been observed to correlate with resistance to a wide variety of drugs both in vitro and clinically. Correlations have been found between HER-2 overexpression and resistance of breast tumour cells in vitro to a wide variety of agents, including alkylating agents such as cis-platinum and CTX, 36 tumour necrosis factor 37 and natural killer cells. 38 Several clinical studies have also shown an association between HER-2 overexpression and drug resistance to alkylating agents, anthracyclines and CMF-like regimens. 32, [39] [40] [41] Additional studies have shown a correlation between HER-2 overexpression and tamoxifen [42] [43] [44] [45] and hormone therapy 25, 46 resistance in breast cancer. Alternatively, the poor prognosis associated with HER-2 overexpression may occur as a result of increased proliferation and metastasis as indicated by other studies. 13, 24, 47 In another recent study, HER-2 overexpression was described as having both prognostic and predictive value with regard to adjuvant therapy in patients with lymph node positive breast cancer. 48 Other biomarkers, eg estrogen receptor, high S-phase fraction, p53 mutation may also contribute to estimating prognosis. Together with our findings, this could be of potential clinical relevance in assisting with treatment decisions for alternative or more aggressive treatments for selected patients.
In conclusion, in this small retrospective study, we identified a potential prognostic factor relating to the overexpression of HER-2 in plasma in women with MBC undergoing HDCT and ABSC transplantation. In multivariate analysis, HER-2 was an independent prognostic factor for predicting progression-free and overall survival. Although several variables (age, hormone receptor status, previous hormone treatment) were analysed by univariate and multivariate analysis in this study, more valuable information will be obtained from a larger prospective study currently underway and may confirm this biomarker as an independent prognostic factor.
